Skin Tape Harvesting for Transcriptomics Analysis

Inclusion Criteria: 1. Male or female between ages of 18 to 75 years 2. Psoriasis Group Only: Clinical diagnosis of moderate to severe plaque psoriasis at least 6 months prior to enrollment with a PASI equal to 5 or greater and PGA 3-4; 3. Psoriasis Group Only: Have lesional and non-lesional skin appropriate for biopsy which has not been treated with topical therapies 2 weeks prior to biopsy collection; 4. Psoriasis Group Only: Lesional skin for biopsy must have a Target Lesion Severity Score equal to 6 or greater; 5. Psoriasis Group Only: If subject was on biologic therapy, lesion to be biopsied should have minimal response to therapy; 6. Psoriasis Group Only: Psoriatic plaque lesion for biopsy on skin areas typically affected by psoriasis and representative of overall disease severity; 7. Healthy controls will have neither history of skin diseases nor current evidence of other active inflammatory skin disease. Exclusion Criteria: 1. Diagnosis of erythrodermic psoriasis, generalized or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis. 2. Evidence of skin conditions other than psoriasis that would interfere with the evaluations. 3. Use of systemic anti-psoriasis therapies within 28 days of study initiation, or three times the half-life of the drug, whichever is longer; 4. Use of UVB therapy or moderate strength non-steroidal topical treatments on lesion to be biopsied within 14 days of study initiation; 5. Current enrollment in investigational device or investigational drug trial(s), or receipt of any investigational agent(s) within 28 days before baseline visit; 6. Use of JAK inhibitor within 4 weeks of screening; 7. Known HIV-positive status or known history of any other immuno-suppressing disease; 8. Exposure to hepatitis B or hepatitis C or to high risk factors for hepatitis B or C, such as intravenous drug use in patient; 9. Pregnant or nursing females; 10. Subjects with a history of keloid formation or hypertrophic scarring; 11. Individuals who have lidocaine sensitivity.